Human CLEC9A Stable Cell Line - CHO-K1

Human CLEC9A, also known as CD370 or DNGR-1 (Dendritic Cell Natural Killer Lectin Group Receptor-1), is a group V C-type lectin-like receptor encoded by the CLEC9A gene located on chromosome 12p13.2. This type I transmembrane protein functions as an activation receptor predominantly expressed on BDCA3+ conventional dendritic cells (cDC1s), where it plays a critical role in sensing cellular damage by recognizing exposed F-actin as a damage-associated molecular pattern. The Human CLEC9A Stable Cell Line - CHO-K1 is engineered by transfecting the human CLEC9A gene into the CHO-K1 host cell line, generating a stable, homogeneous population that constitutively expresses high levels of human CLEC9A on the cell surface. This recombinant cell line provides a reliable and reproducible in vitro platform for studying CLEC9A-mediated signaling, ligand binding, and receptor function without the need for primary dendritic cell isolation, which is technically challenging and yields limited cell numbers.

This stable cell line serves as a valuable tool for a broad range of research and drug discovery applications. It can be used to screen and characterize antibodies, bispecific molecules, or small molecule compounds that target CLEC9A, an emerging immune checkpoint and antigen-targeting receptor in cancer immunotherapy. Researchers can employ this cell line in flow cytometry-based binding assays, cell-based ELISA, or functional assays to evaluate ligand-receptor interactions and downstream signaling events. Additionally, the Human CLEC9A CHO-K1 stable cell line supports the development of CLEC9A-targeted vaccines and dendritic cell-based immunotherapies, as CLEC9A has been shown to mediate cross-presentation of dead-cell-associated antigens and promote cytotoxic CD8+ T cell responses. The stable expression system ensures consistent performance across experiments, making it suitable for high-throughput screening campaigns, potency assays for biologics, and mechanistic studies of CLEC9A in innate and adaptive immunity.